Novel Psychoactive Substances: Stimulants and hallucinogens
New Psychoactive Substances (NPS) are an emerging problem in clinical and forensic toxicology. Their analytical detectability in case work is difficult as long as the new drugs are not yet known and reference standards are missing. The principle of drug design for NPS will be discussed and the variability of chemical structures presented. In contrast to immunoassays, mass spectral methods allow quick implementation of such drugs in target or general screening approaches. For quantification, reference standards and full validation are mandatory and corresponding aspects will be discussed. Another problem is the interpretation of blood levels because reference levels from controlled clinical trials are not available. Thus, blood levels from case work have to be collected together with the clinical signs to setup a suitable reference database. A critical discussion of the limits of such data will close the presentation.